Rabies-based vaccine induces potent immune responses against Nipah virus

Keshwara, Rohan; Shiels, Thomas; Postnikova, Elena; Kurup, Drishya; Wirblich, Christoph; Johnson, Reed F.; Schnell, Matthias J.

doi:10.1038/s41541-019-0109-5

Cited by 35 publications

(31 citation statements)

References 55 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 The bivalent rabies virus vaccine is in pipeline against the NiV and rabies virus, as it has shown good immune response in animal model. 32 The described vaccines were mainly tested on animals and not licensed for the NiV treatment in humans. All reported vaccines primarily composed of single viral protein, and it is a well-known phenomenon that, RNA viruses have a high mutation rate, to prompt alteration of viral genome and proteome.…”

Section: Discussionmentioning

confidence: 99%

Strategic Development of a Next-Generation Multi-Epitope Vaccine To Prevent Nipah Virus Zoonotic Infection

et al. 2019

View full text Add to dashboard Cite

Nipah virus (NiV) is an emerging zoonotic pathogen, reported for the recent severe outbreaks of encephalitis and respiratory illness in humans and animals, respectively. Many antiviral drugs have been discovered to inhibit this pathogen, but none of them were that much efficient. To overcome the complications associated with this severe pathogenic virus, we have designed a multi-epitope subunit vaccine using computational immunology strategies. Identification of structural and nonstructural proteins of Nipah virus assisted in the vaccine designing. The selected proteins are known to be involved in the survival of the virus. The antigenic binders (B-cell, HTL, and CTL) from the selected proteins were prognosticated. These antigenic binders will be able to generate the humoral as well as cell-mediated immunity. All the epitopes were united with the help of suitable linkers and with an adjuvant at the N-terminal of the vaccine, for the enhancement of immunogenicity. The physiological characterization, along with antigenicity and allergenicity of the designed vaccine candidates, was estimated. The 3D structure prediction and its validation were performed. The validated vaccine model was then docked and simulated with the TLR-3 receptor to check the stability of the docked complex. This next-generation approach will provide a new vision for the development of a high immunogenic vaccine against the NiV.

show abstract

Section: Discussionmentioning

confidence: 99%

Strategic Development of a Next-Generation Multi-Epitope Vaccine To Prevent Nipah Virus Zoonotic Infection

et al. 2019

View full text Add to dashboard Cite

show abstract

“…That being said, some RABV-based vectors have been shown to stably express up to 4.4 kB of insert, which is more than 50% of their genome size [ 168 ]. RABV vectors have been used for vaccine development against different pathogens, including HIV-1 and Nipah virus [ 169 , 170 , 171 , 172 ]. In the Nipah vaccine study, an RC RABV-based vaccine expressing the Nipah virus (NiV) glycoprotein (G) was created for evaluation in mice.…”

Section: Expansive Repertoire and Selection Of Currently Availablementioning

confidence: 99%

“…In the Nipah vaccine study, an RC RABV-based vaccine expressing the Nipah virus (NiV) glycoprotein (G) was created for evaluation in mice. The vaccine induced a strong neutralizing antibody response that was also cross-reactive against a related Hendra virus [ 172 ]. Specifically, the antibodies were mainly IgG2c, which suggested a Th1-biased response [ 172 ].…”

Section: Expansive Repertoire and Selection Of Currently Availablementioning

confidence: 99%

Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats

et al. 2020

View full text Add to dashboard Cite

Vaccination is arguably the most cost-effective preventative measure against infectious diseases. While vaccines have been successfully developed against certain viruses (e.g., yellow fever virus, polio virus, and human papilloma virus HPV), those against a number of other important public health threats, such as HIV-1, hepatitis C, and respiratory syncytial virus (RSV), have so far had very limited success. The global pandemic of COVID-19, caused by the SARS-CoV-2 virus, highlights the urgency of vaccine development against this and other constant threats of zoonotic infection. While some traditional methods of producing vaccines have proven to be successful, new concepts have emerged in recent years to produce more cost-effective and less time-consuming vaccines that rely on viral vectors to deliver the desired immunogens. This review discusses the advantages and disadvantages of different viral vaccine vectors and their general strategies and applications in both human and veterinary medicines. A careful review of these issues is necessary as they can provide important insights into how some of these viral vaccine vectors can induce robust and long-lasting immune responses in order to provide protective efficacy against a variety of infectious disease threats to humans and animals, including those with zoonotic potential to cause global pandemics.

show abstract

“…Several vaccine development strategies have recently been studied in small-animal models, including chimeric rabies-based 88 , virus-like particle (VLP)-based 89 , adenovirus-based 90 , and epitope-based 91, 92 vaccines. Those approaches induced a protection against NiV by triggering a specific response against its envelope glycoprotein G that will require further development using non-human primates to evaluate their efficiency and safety.…”

Section: New Strategies To Control Nipah Virus Infectionmentioning

confidence: 99%

Recent advances in the understanding of Nipah virus immunopathogenesis and anti-viral approaches

2019

View full text Add to dashboard Cite

Nipah virus (NiV) is a highly lethal zoonotic paramyxovirus that emerged at the end of last century as a human pathogen capable of causing severe acute respiratory infection and encephalitis. Although NiV provokes serious diseases in numerous mammalian species, the infection seems to be asymptomatic in NiV natural hosts, the fruit bats, which provide a continuous virus source for further outbreaks. Consecutive human-to-human transmission has been frequently observed during outbreaks in Bangladesh and India. NiV was shown to interfere with the innate immune response and interferon type I signaling, restraining the anti-viral response and permitting viral spread. Studies of adaptive immunity in infected patients and animal models have suggested an unbalanced immune response during NiV infection. Here, we summarize some of the recent studies of NiV pathogenesis and NiV-induced modulation of both innate and adaptive immune responses, as well as the development of novel prophylactic and therapeutic approaches, necessary to control this highly lethal emerging infection.

show abstract

Rabies-based vaccine induces potent immune responses against Nipah virus

Cited by 35 publications

References 55 publications

Strategic Development of a Next-Generation Multi-Epitope Vaccine To Prevent Nipah Virus Zoonotic Infection

Strategic Development of a Next-Generation Multi-Epitope Vaccine To Prevent Nipah Virus Zoonotic Infection

Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats

Recent advances in the understanding of Nipah virus immunopathogenesis and anti-viral approaches

Contact Info

Product

Resources

About